Business Context and Reporting Period
This Form 8-K Current Report for Propanc Biopharma, Inc. covers events occurring on January 22, 2018, and January 23, 2018. The Company, incorporated in Delaware with principal offices in Australia, reported the entry into a material definitive agreement and an amendment to its certificate of incorporation.
Key Financial Metrics and Obligations
The filing details a new debt instrument rather than historical operating performance metrics such as revenue or profit.
- Debt Issuance: Entered into a Securities Purchase Agreement with Power Up Lending Group Ltd. for a convertible promissory note with a principal amount of $153,000.
- Interest Rate: 8% per annum, payable in cash or shares of common stock upon maturity or acceleration.
- Maturity Date: January 22, 2019.
- Transaction Costs: The Company agreed to pay or reimburse $3,000 in fees and expenses to the lender.
- Use of Proceeds: General working capital purposes.
- Capital Structure Change: Authorized common shares increased from 101,500,005 to 400,000,000; authorized preferred shares set at 1,500,005.
Material Changes and Terms
The primary material change is the creation of a direct financial obligation and the potential for significant equity dilution.
- Conversion Terms: The Note is convertible into common stock at a base price of $0.065, subject to a variable conversion price mechanism based on the "Market Price" (average of lowest three closing bid prices over ten days). Conversion is restricted if the lender's beneficial ownership would exceed 4.99% of outstanding shares.
- Prepayment Penalties: Early prepayment incurs significant premiums ranging from 112% to 137% of the face amount plus accrued interest, depending on the timing of prepayment (30 to 180 days post-issuance).
- Default Provisions: Upon an event of default, interest accrues at 22% per annum. The Company may be required to pay a "Default Amount" equal to 150% of the outstanding principal plus accrued interest. Specific default triggers include failure to reserve five times the number of shares issuable upon conversion, delisting, or cessation of operations.
Outlook, Risks, and Contingencies
Management intends to use the proceeds for general working capital. The filing highlights several risks associated with the new debt instrument:
- Dilution Risk: The variable conversion price and low base conversion price ($0.065) could result in substantial issuance of new shares.
- Liquidity and Default Risk: The high prepayment premiums and the 150% default penalty create significant financial pressure if the Company cannot meet its obligations or wishes to refinance early.
- Operational Covenants: The Company is restricted from selling substantially all assets without lender consent. Failure to meet reporting obligations or maintain listing status constitutes an event of default.
- Unregistered Sales: Shares issued upon conversion will be sold pursuant to Section 4(a)(2) of the Securities Act, meaning they are unregistered.
Investor Verification Checklist
- Verify the current "Market Price" of the Company's stock to calculate the actual potential conversion price and dilution impact.
- Confirm the Company's current cash position to assess its ability to service the 8% interest or meet the 150% default penalty if liquidity issues arise.
- Review the Company's compliance with reporting obligations under the Exchange Act to ensure no default triggers regarding delisting or reporting failures are active.
- Check the total number of authorized shares remaining after the recent amendment to understand the capacity for future equity issuance.
- Monitor the Company's ability to reserve the required five times the number of shares issuable upon full conversion to avoid an immediate event of default.